Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

NCT01004861 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01004861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01004861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2009
Completion date
October 25, 2018
Enrollment
132 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor